Merck makes life tough for Teva over Zocor

Merck is cutting the price of the anti-cholesterol blockbuster. Teva: Our generic version will meet our forecasts.

A month ago, Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) obtained US Food and Drug Administration (FDA) marketing approval for a generic version of Zocor, made by Merck & Co. (NYSE:MRK). Merck is not standing idly by, and is taking measures to defend its blockbuster anti-cholesterol drug, which has $4.6 billion in annual sales.

The price for Zocor is likely to drop following reports about negotiations between Merck and various US healthcare organizations. The “Wall Street Journal” reports, “A spokesman at UnitedHealth Group Inc., one of the nation's largest health insurers, said it had negotiated reduced prices for Zocor with Merck…this move will reduce the co-payment for Zocor made by patients at pharmacies to $10 from $25. Moreover, the new generic version of the drug, made by Teva Pharmaceuticals USA, will be in tier three, or the most expensive price group. Generic drugs typically carry cheaper co-pays than branded drugs.”

The “Wall Street Journal” quotes Merck as saying in response, "We don't talk about our contracting strategies. We are going to continue to price Zocor competitively."

In late May, Teva announced that it had obtained conditional FDA marketing approval for Simvastatin tablets, a generic version of Zocor. Teva will be allowed to market 5mg, 10mg, 20mg, 40mg, and 80mg tablets. Teva was the first company to apply for marketing approval for low dosage Simvastatin tablets (5-40mg), and obtained a 180-day exclusive marketing period for its version of the drug.

Leader DS analyst Uri Hershkovitz said this was the first time that a drug company had lowered the price of an ethical drug before generic versions entered the market. He said that, until now, ethical drug companies kept the full price until they lost half their market share.

Teva said in response to the report, "We will meet the original forecasts we gave to the market. When we released the original sales forecast for the generic version of Zocor, we took into account the competitive environment in which we operate."

Published by Globes [online], Israel business news - - on June 21, 2006

© Copyright of Globes Publisher Itonut (1983) Ltd. 2006

View comments in rows
Update by email about comments talkback
Your name
Please insert your name
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Erez Vigodman Teva boosted by European drug recommendations

Teva's share jumped 4% in Tel Aviv, after climbing 4.9% on Wall Street.

Partner/Orange Partner launches smartphone medical services

The new services includes prescriptions, hospital referrals, and confirmation of illness.

Reuven Krupik Clal Biotech unit PolyHeal nears licensing deal

PolyHeal has signed an MOU with a European drug company for an exclusive global license.

Nasdaq Galmed jumps on FDA hepatitis drug approval

The FDA awarded Fast Track Designation to aramchol for the treatment of Non-Alcoholic Steato-Hepatitis.

artificial sweeteners Weizmann Inst: Sweeteners cause diabetes, obesity

A study found that artificial sweeteners adversely affect intestinal bacteria.

BioCancell share jumps on positive cancer trial results

The clinical trials demonstrated safety and effectiveness of the treatment on high-risk bladder cancer patients.

Trendlines Group set for Toronto IPO

The technological incubators company is raising C$9 at a company value of C$80 million, after money.

Reuven Krupik Clal Biotech sues Hyperion for $200m

Clal Biotechnology alleges Hyperion made "rash and ill-considered" decisions in the Andromeda affair.

pharmaceuticals Clal Biotech: No evidence of misconduct by us

Clal Biotech says documents it was shown by Hyperion do not indicate it committed any misconduct regarding Andromeda.

Soroka Hospital  picture: Eyal Yitzhar Visiting Israel’s wounded at Soroka

Soroka Medical Center in Beersheva, the Israeli hospital closest to Gaza, bears the medical brunt of Operation Protective Edge.

Twitter Facebook Linkedin RSS Newsletters גלובס